ZLAB - Turning Point and Zai Lab fall after lung cancer data for repotrectinib in China

Chinese biotech Zai Lab (NASDAQ:ZLAB) and California-based precision oncology company, Turning Point Therapeutics (NASDAQ:TPTX) are trading lower on Thursday after reporting topline data from China for its lung cancer candidate, repotrectinib, from a Phase 1/2 trial. The TRIDENT-1 is a global trial designed to evaluate Turning Point’s (TPTX) lead asset in ROS1-positive TKI-naïve non-small cell lung cancer (NSCLC). In terms of the primary objective, the results indicated a confirmed objective response rate (cORR) of 91% (10/11) in China subpopulation for TKI-naïve cohort (EXP-1). For the global trial, cORR stood at 79% among 71 TKI-naïve patients. The secondary endpoint of the duration of response (DOR) range reached 3.6+-7.5+ months for the TKI-naïve China subpopulation with a median DOR follow-up of 3.7 months, the companies said. The enrollment for the global trial is currently underway. Zai Lab (ZLAB) plans to submit TKI-naïve data to Chinese regulators in 4Q 2022. “It is encouraging to

For further details see:

Turning Point and Zai Lab fall after lung cancer data for repotrectinib in China